Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102281 | 0.98 | MAPT (0.31) | MAPTKDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL20369879 | 0.94 | MAPT (0.34) | MAPTKDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL676103 | 0.94 | MAPT (0.34) | MAPTKDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL10102396 | 0.92 | MAPT (0.33) | MAPTKDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL10102285 | 0.92 | MAPT (0.33) | MAPT | |
| SCHEMBL12424707 | 0.91 | MAPT (0.33) | MAPTKDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL10106918 | 0.91 | MAPT (0.34) | MAPTKDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL10102278 | 0.90 | IDH1 (0.30) | — | |
| SCHEMBL10102413 | 0.90 | PDK2 (0.33) | — | |
| SCHEMBL13343262 | 0.89 | TSHR (0.32) | KDM4EALDH1A1TSHRHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8663508-B2 | Photochromic curable composition | TOKUYAMA CORPORATION (JP) | 2014-03-04 | — | — | US | disclosed |
| US-20130015416-A1 | PHOTOCHROMIC CURABLE COMPOSITION | TOKUYAMA CORPORATION (JP) | 2013-01-17 | — | — | US | disclosed |
| US-8308995-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| EP-2275418-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120138876-A1 | CHROMENE COMPOUND | KASAI SOKO (JP) | 2012-06-07 | — | — | US | disclosed |
| US-8147726-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20110062396-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
| EP-2275418-A1 | CHROMENE COMPOUND | Tokuyama Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120138876-A1 | CHROMENE COMPOUND | CHRM1, CBX8, CBX7 | MAPT 3134/4885KDM4E 1435/4885MEN1 270/4885 |
| US-20110062396-A1 | CHROMENE COMPOUND | CDYL, NR0B1, NR1H2 | MAPT 4740/4885KDM4E 2629/4885MEN1 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.